The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.
 
Omar Nadeem
Consulting or Advisory Role - Adaptive Biotechnologies; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; GPCR Therapeutics; Janssen; Karyopharm Therapeutics; Takeda
Research Funding - Janssen (Inst); Takeda (Inst)
 
Robert Redd
No Relationships to Disclose
 
Clifton Craig Mo
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi
 
Jacob Laubach
No Relationships to Disclose
 
Julia Prescott
No Relationships to Disclose
 
Amada Metivier
No Relationships to Disclose
 
Christine Davie
No Relationships to Disclose
 
Meredith Bertoni
No Relationships to Disclose
 
Elizabeth Murphy
No Relationships to Disclose
 
Brian Sheehan
No Relationships to Disclose
 
Kelsey Tague
No Relationships to Disclose
 
Hira Shrestha
No Relationships to Disclose
 
Rebekah Medina
No Relationships to Disclose
 
Alexandra Distaso
No Relationships to Disclose
 
Houry Leblebjian
No Relationships to Disclose
 
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Oncopeptides; Sanofi; Secura Bio; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Oncopeptides (Inst); Takeda (Inst)
 
Irene M. Ghobrial
Employment - Disc Medicine (I)
Honoraria - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Cellectar; Janssen; Karyopharm Therapeutics; Medscape; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Cellectar; CohBar; Curio Science; Dava Oncology; Genentech; GlaxoSmithKline; GNS Healthcare; Huron Consulting; Janssen; Karyopharm Therapeutics; Magenta Therapeutics; Medscape; Menarini silicon biosystems; Novartis; Noxxon Pharma; Oncopeptides; Pfizer; PureTech; Sanofi; Sognef; Takeda; The Binding Site
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Janssen Oncology; Millennium; Novartis; Onyx; Takeda